FOXO4-DRI dosing (preclinical regimens)
> Updated:
Calculate the FOXO4-DRI dose
The calculator is already set up for FOXO4-DRI — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (3 consecutive days) | 0.5–1 mg subcutaneously per day | Starting dose |
| Main cycle (3 consecutive days) | 2–2.5 mg subcutaneously per day | Increase if needed |
| Cycle ceiling; cycle repeated 2–3x per year | up to 5 mg subcutaneously per day | Maximum in this schedule |
Practical dosing and effect details
In the study by Baar and colleagues (Cell, 2017, volume 169), mice received FOXO4-DRI at 5 mg/kg every other day, three injections total, rather than daily and continuously. That intermittent pattern selectively triggered apoptosis in senescent cells rather than healthy ones, and in old mice it restored fur density, kidney function, and physical fitness.
That mouse dose (mg/kg, intravenous) does not carry over directly to the human schedule on this page: the 0.5-5 mg subcutaneous, short 3-day cycles shown above come from preclinical work and open community protocols, not from the Baar study's own dosing. What the two sources share is the underlying principle: a short cycle with a break rather than continuous administration. No human clinical trials of FOXO4-DRI exist.
This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.FOXO4-DRI10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =FOXO4-DRI5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 1 mg dose:1 mg = 0.2 ml= 20 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
FOXO4-DRI: reference regimens
Controlled data on this compound are limited.
FOXO4-DRI is given subcutaneously in short courses (a senolytic pattern, a few consecutive days, with the cycle repeated a few times per year).
FOXO4-DRI dosing in the preclinical study and in community protocols is built the same way, on a short cycle with a break rather than daily use: that is a deliberate senolytic design choice, not a supply constraint.
More scientific background in the FOXO4-DRI monograph
Notes and safety
- • FOXO4-DRI is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
FOXO4-DRI